文献速递消化道肿瘤与早癌肝病

mRECIST标准客观缓解作为晚期肝细胞癌总生存期的预测因子和潜在替代终点

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
PubMed 文献 · J Hepatol · 2017-01-26

本研究基于BRISK-PS随机III期试验(比较brivanib与安慰剂)的个体患者数据,纳入334例有随访影像的晚期肝细胞癌患者,采用时间依赖协变量分析评估mRECIST客观缓解对总生存期的预测价值。结果显示客观缓解是独立预后因素(HR=0.48),且与生存概率高度相关(R=-0.92),可作为候选替代终点,但需进一步研究支持。

要点

  • mRECIST客观缓解是晚期肝细胞癌总生存期的独立预测因子(HR=0.48)。
  • 客观缓解与生存概率高度相关(R=-0.92),支持其作为候选替代终点。
  • 客观缓解出现较早(中位至缓解时间1.4个月),可早期反映治疗效应。

核心结论

  • mRECIST客观缓解可预测晚期肝细胞癌患者的总生存期,可作为候选替代终点,但需进一步研究支持。

研究设计与样本

  • 基于BRISK-PS随机III期试验(brivanib对比安慰剂)的个体患者数据,纳入随访期间有可用影像扫描的患者334例(占随机化患者的85%)。

主要发现

  • brivanib组和安慰剂组的客观缓解率分别为11.5%和1.9%。
  • 客观缓解与更好的生存相关(中位总生存期15.0个月 vs 9.4个月,p<0.001)。
  • 客观缓解具有独立预后价值(HR=0.48;95%CI 0.26-0.91,p=0.025)。
  • 客观缓解作为总生存期替代终点显示出有希望的结果(R=-0.92;95%CI -1至-0.73,p<0.001)。
  • 客观缓解是治疗效应的早期指标(中位至客观缓解时间1.4个月)。

局限性

  • 需要进一步研究来支持该发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this end-point as a potential surrogate of OS. METHODS: Individual patient data from the BRISK-PS randomized phase III trial comparing brivanib vs. placebo (the first to prospectively incorporate mRECIST) were used to analyze objective response as a predictor of OS in a time-dependent covariate analysis. Patients with available imaging scans during follow-up were included (n=334; 85% of those randomized). Moreover, a correlation of the survival probability in deciles vs. the observed objective response was performed to evaluate its suitability as a surrogate end-point. RESULTS: Objective response was observed in 11.5% and 1.9% of patients treated with brivanib and placebo respectively, and was associated with a better survival (median OS 15.0 vs. 9.4months, p<0.001). In addition, objective response had an independent prognostic value (HR=0.48; 95% confidence interval [CI], 0.26-0.91, p=0.025) along with known prognostic factors. Finally, objective response showed promising results as a surrogate of OS in this trial (R=-0.92; 95% CI, -1 to -0.73, p<0.001). It was an early indicator of the treatment effect (median time to objective response was 1.4months). CONCLUSIONS: Objective response by mRECIST in advanced HCC predicts OS and thus can be considered as a candidate surrogate end-point. Further studies are needed to support this finding. LAY SUMMARY: There is a need to identify surrogate end-points for overall survival in advanced hepatocellular carcinoma. We studied patients from the phase III BRISK trial, comparing brivanib treatment with placebo after sorafenib progression. We demonstrate that objective response is an independent predictor of survival and qualifies as a potential surrogate end-point for overall survival in this patient population. CLINICAL TRIAL NUMBER: NCT00825955.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017. PMID: 28131794. doi:10.1016/j.jhep.2017.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。